$14.83
-0.08 (-0.54%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CRVS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 1 with posted results
Held by 9 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, D. E. Shaw & Co., Inc., +4 more) · FINRA short interest 22.5 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaNCT06561048Progression-free survivalRandomized · Open-label · Treatment | Phase 3 | Recruiting | Drug: Soquelitinib, Belinostat, Pralatrexate | Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell | 150 | Nov 2027 | ≤ 468 d | 2026-04-08 |
| Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADNCT07441395Percent change from baseline in Eczema Area and Severity Index (EASI) score at Week 12Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: Soquelitinib, Placebo | Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic | 200 | Jun 2027 | ≤ 315 d | 2026-03-05 |
| A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaNCT03952078Incidence, nature, and severity of adverse events following treatment with CPI 818 to establish the safety and tolerability with increasing doseNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: CPI-818 | T-cell Lymphoma | 151 | 2026-04-30 | — | 2025-04-16 |
| Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADNCT06345404Incidence of adverse events, changes in laboratory values, vital signs, and electrocardiogramsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Soquelitinib, Placebo | Atopic Dermatitis | 82 | 2026-01-28actual | — | 2026-03-12 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab.Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2022-12-28actual | — | 2023-12-21 |
| Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaNCT04280328Safety and tolerability of ciforadenant in combination with daratumumab relapsed / refractory multiple myeloma.Open-label · Treatment | Phase 1 | Completed | Drug: Ciforadenant, daratumumab | Multiple Myeloma | 7 | 2021-09-21actual | — | 2022-03-11 |
| CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 PatientsNCT04734873results2022-08-23Proportion of Participants Alive and Respiratory Failure Free of CPI-006 Plus SOC Versus Placebo Plus SOCRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision. Not related to safety issues. | Drug: CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC | Covid-19 | 46 | 2021-08-18actual | — | 2022-09-21 |
| Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersNCT02655822Incidence of dose-limiting toxicities (DLTs) of ciforadenant as a single agent and in combination with atezolizumabRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: Ciforadenant, Ciforadenant, Ciforadenant, Ciforadenant + atezolizumab, Ciforadenant | Renal Cell Cancer, Metastatic Castration Resistant Prostate Cancer | 502 | Jun 2021actual | — | 2021-08-30 |
| Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 PatientsNCT04464395Incidence of Treatment-Emergent Adverse Events to Determine Single Dose of CPI-006 That is Safe in Patients with COVID-19Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: CPI-006 · Other: Standard of Care | COVID-19 | 30 | 2021-03-01actual | — | 2021-07-21 |
| Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female SubjectsNCT03237988AUC0-∞: AUC from time zero to infinityRandomized · Open-label · Other | Phase 1 | Completed | Drug: CPI-444 Capsules, CPI-444 Tablets | Healthy Subjects | 24 | 2017-09-20actual | — | 2018-01-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19